Skip to main content

FDA Listing Inc.

FDA Listing Logo

FDA LISTING INC: EXPERIENCED ADVISORS FOR FULL-SERVICE FDA REGISTRATION & COMPLIANCE

+1 212 444 8202

U.S. FDA Registration

& Labeling Compliance Assistance

FDA Dandruff Monograph M032

FDA Dandruff Monograph M032 outlines conditions that may apply to over-the-counter drug products for controlling dandruff, seborrheic dermatitis, and psoriasis. The monograph includes permitted active ingredients, concentration ranges, labeling, directions, warnings, and related compliance requirements.

OTC Monograph M032: Drugs for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis

Dandruff and medicated scalp products are OTC drug products when they are marketed to control dandruff, seborrheic dermatitis, or psoriasis. FDA Monograph M032 covers certain medicated shampoos, scalp treatments, lotions, creams, gels, and similar topical dosage forms.

 

For brand owners, importers, private-label companies, and manufacturers, key compliance considerations include the active ingredient and concentration, intended use, wash-off or leave-on dosage form, ingredient combinations, Drug Facts labeling, required warnings, directions for use, and FDA drug establishment registration and drug-listing requirements.

Dandruff and Medicated Scalp Product Categories

FDA Monograph M032 may apply to anti-dandruff shampoos, medicated shampoos, seborrheic dermatitis shampoos, psoriasis shampoos, scalp treatments, coal-tar products, pyrithione zinc shampoos, selenium sulfide shampoos, salicylic acid products, and sulfur scalp products. The product format alone does not determine whether a product fits the monograph. Also review the active ingredient, concentration, intended use, dosage form, wash-off or leave-on use, directions for use, warning statements, and labeling claims. A product’s claims should match the applicable active ingredient conditions and the finished formulation.

 

Products marketed to treat hair loss, alopecia, fungal scalp infections, lice, scalp infections, scalp wounds, eczema, or other conditions may fall under a different FDA regulatory framework. A dandruff or medicated scalp product should not use claims that exceed its applicable M032 conditions.

Common Dandruff and Medicated Scalp Active Ingredients

Active Ingredient Concentration Range Common Product Terms
Coal tar 0.5% to 5% Coal-tar shampoo, dandruff shampoo, psoriasis scalp treatment
Pyrithione zinc 0.3% to 2% for wash-off products; 0.1% to 0.25% for leave-on products Pyrithione zinc shampoo, anti-dandruff shampoo, scalp treatment
Selenium sulfide 1% Selenium sulfide shampoo, medicated dandruff shampoo
Micronized selenium sulfide 0.6% Medicated dandruff shampoo, selenium sulfide scalp product
Salicylic acid 1.8% to 3% Salicylic acid shampoo, scalp exfoliating treatment, psoriasis shampoo
Sulfur 2% to 5% Sulfur shampoo, dandruff treatment, scalp treatment

FDA Monograph M032 includes different active ingredient conditions depending on whether the product is intended for dandruff, seborrheic dermatitis, or psoriasis. For example, pyrithione zinc is included for dandruff products and certain wash-off seborrheic dermatitis products, while coal tar and salicylic acid have conditions that may apply across multiple M032 categories. This table provides a simplified overview and does not replace a review of the complete monograph.

Key Dandruff and Medicated Scalp Labeling Points

Review dandruff and medicated scalp product labeling as part of the finished product’s overall compliance position. Active ingredients, concentration, intended use, dosage form, wash-off or leave-on use, Drug Facts content, warnings, directions, principal display panel statements, and online marketing should align with the product’s applicable conditions.

Product Claims

Dandruff and medicated scalp claims should match the active ingredient, concentration, intended use, and finished product dosage form. Depending on the applicable monograph condition, products may be marketed to control dandruff, seborrheic dermatitis, or psoriasis and to relieve associated symptoms such as flaking, scaling, and itching.

 

A product should not use broader claims for hair growth, hair-loss treatment, scalp infection treatment, fungal scalp infections, eczema, lice treatment, or other conditions outside the applicable M032 conditions. Claims on packaging, ecommerce listings, retailer descriptions, websites, social media, and advertising should match the Drug Facts panel.

Active Ingredient Statements

The Drug Facts panel should identify each active ingredient and its concentration, together with the corresponding purpose. The product name, front-label claims, and terms such as “antidandruff shampoo,” “medicated shampoo,” “seborrheic dermatitis treatment,” or “psoriasis scalp treatment” should match the product’s active ingredient and permitted intended use.

 

If a dandruff or medicated scalp product contains more than one active ingredient, review the formulation and labeling for applicable combination conditions. Do not assume that separately permitted active ingredients can be combined in any concentration, dosage form, or claim combination.

Warnings and Directions

Dandruff and medicated scalp products generally require product-specific warning statements and directions. Depending on the active ingredient and intended use, warnings may address external use only, avoiding eye contact, discontinuing use if irritation occurs, and consulting a doctor if the condition worsens or does not improve. Coal-tar products should include applicable warnings regarding increased sensitivity to sunlight. Product labeling and use instructions should address appropriate precautions for sun exposure after use.

 

Directions should match the active ingredient, product type, dosage form, wash-off or leave-on use, application frequency, and applicable age group. Medicated shampoos generally include instructions to wet hair, apply the product, lather, leave on the scalp for the labeled period when applicable, rinse thoroughly, and repeat as directed.

Drug Facts Labeling

Dandruff and medicated scalp products should include appropriate Drug Facts information, including active ingredients, purpose, uses, warnings, directions, and inactive ingredients. The Drug Facts panel should correspond to the finished product that is commercially distributed.

 

Review product names, dandruff claims, seborrheic dermatitis claims, psoriasis claims, website content, retailer product descriptions, and advertising for consistency with the Drug Facts panel. Claims on ecommerce listings, social media, and other marketing materials should not expand the product’s permitted intended use.

FDA Monograph Information

This page provides a simplified overview of FDA OTC Monograph M032. It does not include every active ingredient, concentration range, permitted combination, dosage-form requirement, testing requirement, labeling detail, warning, direction, or FDA administrative order that may apply to a specific dandruff, seborrheic dermatitis, or psoriasis product.

 

For complete and current requirements, including active-ingredient conditions and administrative orders applicable to OTC dandruff, seborrheic dermatitis, and psoriasis drug products, review the related official FDA monograph resource.

FDA Dandruff Compliance Services

Dandruff and medicated scalp product compliance involves more than selecting an active ingredient. A product review may include active ingredients, concentration levels, intended use, dosage form, wash-off or leave-on conditions, ingredient combinations, labeling claims, Drug Facts labeling, warnings, directions, manufacturing activities, and drug-listing information.

We assist with:

  • Drug Establishment Registration
  • OTC Drug Listing
  • NDC Labeler Code
  • OTC Drug Label Review
  • Drug Master File

Need help with an FDA-regulated dandruff or medicated scalp product? Our team can assist with Drug Establishment Registration, OTC Drug Listing, NDC Labeler Codes, OTC Drug Label Review, and Drug Master Files.

Frequently Asked Questions (FAQ)

Generally, yes, when it is marketed to control dandruff, seborrheic dermatitis, psoriasis, or related symptoms such as itching, flaking, or scaling. The product’s claims and intended use help determine its regulatory status.
FDA Monograph M032 covers certain OTC drug products for controlling dandruff, seborrheic dermatitis, and psoriasis. It includes conditions for permitted active ingredients, concentration ranges, labeling, warnings, directions, and product uses.
Yes. M032 includes pyrithione zinc and selenium sulfide under applicable product conditions. Pyrithione zinc concentration ranges depend on whether the product is wash-off or leave-on, while selenium sulfide is listed at 1% and micronized selenium sulfide at 0.6%.
Not under standard M032 conditions. Claims should remain limited to permitted dandruff, seborrheic dermatitis, or psoriasis uses and should not expand into hair-loss, scalp-infection, or other disease-treatment claims.
Generally, yes. OTC dandruff and medicated scalp drug products should include Drug Facts information for the active ingredient, purpose, uses, warnings, directions, and inactive ingredients.
Drug establishment registration and drug listing may apply to companies that manufacture, process, package, repack, or relabel OTC dandruff and medicated scalp products for commercial distribution. The required listing arrangement depends on the company’s role.

_______ Related Services _______